Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sinovac's Varicella Vaccine in Healthy Population Aged ≥13 Years
NCT05015686Phase 3Enrolling by invitation
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of varicella vaccine live in varicella (VZV), sponsored by Sinovac Biotech Ltd.. Started Sep 2021; status: enrolling by invitation.
02
Drugs
varicella vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT05015686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015686.